For CJC-1295 DAC there are no particular diet restrictions that need to be followed due to its long half-life. For GHRP products the following should be observed as insulin and fatty acids can blunt the release of GH in the body and therefore make your injections less effective: •Avoid eating/drinking anything high in fat for 3 hours before your injection and anything high in carbohydrates for 1-2 hours (always do your injection on an empty stomach). •Wait at least 20 minutes after your injection before eating/drinking anything with calories.

I can't believe we as Aussies are the 1st to point the finger of other countries on drug cheats, as soon as its in our own backyard and one of our afl footy teams, we seem to downplay the seriousness of drugs in sport, its crazy, and to think they didnt know what was being injected, doh. my favorite is the Shane Warne Diuretics that his mum gave him, lol, 12 month ban, Essendon minimum 2 year ban.....has to be.
Paracetamol has long been considered very safe, without the risks of gastric injury associated with aspirin and NSAIDs. But there are distinct risks of liver injury, usually following overdose situations. In response many international regulatory authorities have taken steps to reduce the pack sizes of paracetamol, and to restrict release in some environments to pharmacies. In the USA, FDA has required prescription acetaminophen, when it is usually combined with an opioid, to reduce the dose per dose unit to 325 mg, but without reducing the maximal daily dose. No change of dosing in the USA has yet come for OTC acetaminophen. Use of paracetamol should be kept to a minimum in patients with underlying liver and renal disease. It can reduce the effects of lithium, ACE inhibitors, beta blockers and methotrexate. However, it remains one of the safest and most effective analgesic drugs, particularly in the elderly where the risks of gastric bleeding with NSAIDs are more common, and carries minimal side effects.
The biggest negative, and this is a big one, is that AOD9604 has undergone very rigorous scientific testing, and has been found to have no effect in humans (3). When AOD9604 was first developed, it showed significant promise as a weight loss treatment. A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis, or fat burning (5). Subsequent studies in obese mice and rats attempted to show that the peptide works to burn fat in the same way as human growth hormone, but found that this was not the case, meaning that the fact this peptide resembled hGH was meaningless. Scientists were unable to determine how this peptide was working in mice (6).
All our peptides are prescribed by experienced anti-ageing doctors, and arrive directly to you from the pharmacy. The prescription will include your name, product name, dose, and potency. The product arrives cold packed and reconstituted, ready to use. All of our peptides that are in injectable form also come with the syringes and swabs needed to complete your course.
Growth hormone releasing peptide (GHRP) 2 is a type of peptide therapeutic that mimics the effects of ghrelin, the “hunger hormone”. Ghrelin is a hormone that helps regulate appetite as well as energy distribution and rate of use, or metabolism. In the 1980’s, ghrelin was discovered to be the body’s natural ligand (or binding molecule) of the GHRP receptor in the anterior pituitary. This was a significant discovery, as it highlighted the role of ghrelin in hGH secretion and growth regulation. Modern biotechnology has used this knowledge to develop peptides that can be administered to mimic ghrelin’s hGH stimulation, but in a more targeted fashion. GHRP 2 is one such peptide, stimulating hGH secretion by 7-15 times, increasing appetite and meal initiation, while also decreasing fat mass and cholesterol. GHRP 2 is ideal for patients who are hypercatabolic, due to critical illness, cancer, AIDS, etc. It should be noted that GHRP 2 can also increase levels of prolactin, aldosterone, and cortisol.

In June 2011 the Advisory Committee on Medicines Scheduling was referred a proposal by the delegate to consider up-scheduling of five (5) then unscheduled substances contained in cold and cough preparations into Schedule 2. One of these substances was phenylephrine and many public submissions received rejected this proposal on the grounds of the paracetamol/phenylephrine exemptions in the Schedule 2 entry. The committee made similar comments and the delegate agreed that the current exempt from scheduling status of phenylephrine was appropriate.

IGF-1 is so named because of its close resemblance to insulin. Because IGF-1 is so similar to insulin, it interacts with insulin receptors on the surface of your cells, produces some of the same effects as insulin and even magnifies the effect of insulin. For example, one primary effect of both excess insulin and excess IGF-1 is hypoglycemia (low blood glucose). When you workout for a long time (longer than about one hour) your liver increases its release of IGF-binding protein (IGFBP-3) to prevent the onset of hypoglycemia that would otherwise happen as a result of the increased release of IGF-1 that occurs during training.
Nevertheless, the hypothesis that AOD9604 does not activate the hGH/IGF-1 axis had to be tested in humans. The studies presented here confirm the in-vitro results. In these studies no clinically relevant changes of IGF-1 levels were observed and no differences to the placebo treatment were found. Together with the lack of any other symptoms associated with known IGF-1 mediated effects, such as sodium retention, tissue oedema, hypertension, or impaired glucose tolerance, the results demonstrate that AOD9604 does not activate the hGH/IGF-1 pathway and therefore has no growth promoting effect.
In June 2007, the NDPSC decided to extend the exemption from the limit on paracetamol combinations being allowed as general sale products to include phenylephrine (as long as it also qualified as exempt from scheduling through the phenylephrine entries). At that time, the NDPSC considered that the safety profile of these substances was such that allowing a fixed combination to be unscheduled was reasonable.
AOD9604: AOD9604 is a synthetic peptide taken orally. The small peptide mimics a section of the growth hormone molecule which increases fat metabolism and decreases the production of fat. AOD9604 is claimed to reduce fat, increase muscle mass and possibly help recover from joint cartilage damage. However, there is currently no published human data to support these claims. AOD9604 is not approved for human use, but is used in sport for weight loss and muscle enhancement and the perception that it helps recover from tissue damage. This drug was highlighted in the Australian Crime Commission report on Organised Crime and Drugs in Sport. No significant adverse effects have been reported yet, but AOD9604 is now prohibited by WADA.
Some athletes and bodybuilders help their body with the weight loss process using peptides like GHRP-2, a growth hormone releasing peptide. GHRP-2 has been shown to increase bone density and cellular repair, increase lean body mass, decrease body fat, and improve sleep. Combined with a reduced calorie diet and exercise program, GHRP-2 can help you achieve your weight loss and fitness goals faster.
Peptide therapy encompasses numerous different drugs with varied effects, ranging from immune modulation and tissue repair to fat loss and muscle building. Our center has seen very positive results in patients with CFS, Hashimoto’s thyroiditis, Lyme disease, and fibromyalgia, among other conditions. Ask your physician or speak to a patient representative at (877) 508-1177 to find out if peptide therapy is right for you.
One submission was received, which did not support the delegate's interim decision, as available data support that the fixed dose paracetamol/caffeine combination product provides clinically meaningful efficacy over paracetamol alone; has an excellent safety profile; a very low risk of nephrotoxicity, toxicity in overdose, misuse, abuse or illicit use; and a highly favourable risk/benefit profile.
In the multiple dose and long term studies, AOD9604 was well tolerated over the entire dose range. In none of the studies did any drug-related withdrawals or drug-related serious AEs occur. No drug related clinically significant AEs, or changes of clinical significance in vital signs, safety laboratory tests or ECGs were detected during the studies. There were no observable trends in the incidence of AEs between the 0.25 mg, 0.5 mg, 1 mg, 9 mg and 27 mg AOD9604 and placebo treatment groups. The highest dose administration (54 mg), however, was associated with an increased incidence of GI-related AEs.

Background: The human growth hormone (hGH) has properties making it a potential candidate to treat obesity, however safety issues limit its long-term use. AOD9604 is a peptide fragment of the C-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD9604 obtained in clinical trials are summarized.


Many patients use Ipamorelin short term (3-6 months) for fat loss benefits and overall improvements in body composition. Ipamorelin increases fat metabolism, so when age starts to become a factor in a person’s ability to lose weight, this peptide can create a more efficient and sometimes faster process. Patients that are also physically active tend to notice even faster benefits while using Ipamorelin, as it aids recovery from workouts and allows for faster progression and typically more fat loss. Once a patient’s desired weight has been achieved, Ipamorelin use can be discontinued, and weight maintenance can be achieved through diet and lifestyle changes.

Metabolic Pharmaceuticals have reported that recent in vitro trials have shown that AOD9604 may stimulate the growth of bone cells, and muscle and cartilage cells. These results have not yet been reproduced in animals or humans (4). There was a lot of speculation that Metabolic was providing AOD9604 to players at the Essendon Football Club as part of a secret clinical trial, but the company has flatly denied this claim, claiming it has not run any human trials since 2007 (2). AOD9604 has been scientifically proven safe and side-effect free (2), and is apparently very difficult to detect in the blood.


The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.
If there's one thing that science has definitively said about AOD9604, it is that it is safe and has no side effects. Calzada, after trying the peptide out as an anti-obesity and anti-arthritic, has succeeded in having the peptide declared "Generally regarded as safe" by the FDA, which makes it legal to use as a food additive in America. Calzada, seemingly under no pretense that their product has pharmaceutical properties, is now trying to break into the US over the counter supplement and "Nutraceutical" market with AOD9604 (2,4). Interestingly, the compound has only been approved for use in levels of up to 1mg per day (2), whereas the doses used in trials generally hovered around 500ug/kg (5,6), which means a 100kg person was receiving 50mg of the peptide daily. There is no science behind the peptide, or the dosage, and Calzada themselves have previously said AOD9604 is not effective orally (2).
Nevertheless, the hypothesis that AOD9604 does not activate the hGH/IGF-1 axis had to be tested in humans. The studies presented here confirm the in-vitro results. In these studies no clinically relevant changes of IGF-1 levels were observed and no differences to the placebo treatment were found. Together with the lack of any other symptoms associated with known IGF-1 mediated effects, such as sodium retention, tissue oedema, hypertension, or impaired glucose tolerance, the results demonstrate that AOD9604 does not activate the hGH/IGF-1 pathway and therefore has no growth promoting effect.

It is well established that hGH is a lipolytic hormone (15), but the exact mechanisms used are still unclear. In this paper we present data that suggest that hGH and its lipolytic fragment (AOD9604) induce their chronic in vivo actions on lipolysis in part by modulating the expression of theβ 3-AR. Human GH has been shown to affect the in vivo expression and function of β-ARs in vivo in sheep (16). Data presented in this paper indicate that chronic administration of hGH influences expression of the β3-AR in adipose tissue in the ob/ob mouse. In brown adipose tissue (BAT), these compounds also increase expression of β3-AR expression in the lean C57BL/6J mouse. The increase in expression induced by chronic hGH or AOD9604 treatment correlated with the decrease in adipose tissue mass. We therefore hypothesize that treatment with either hGH or AOD9604 enhances β3-AR expression, which has been observed in murine 3T3-F442A and human SK-N-MC cells in vitro (11).
The increase in GH secretion due to IPAMORELIN (and other GHRP) leads to an increase in IGF-1 (thought to be the anabolic mechanism of GH).  As we get older GH and subsequently IGF-1 decrease substantially.  This decline is thought to be one of the major causes of the ageing process.  By increasing these levels again there is increased collagen synthesis, promotion of lean muscle mass, bone strength, improved healing capability, improved sleep cycle, increased energy, repair and regeneration of internal organs, strengthening of joints/cartilage/connective tissue, and anti ageing effects on the skin. 
For Growth Hormone (GH) to perform its anabolic (muscle building) affects it requires the presence of the body's most anabolic hormone: insulin. This is in contrast to GH related fat loss which requires insulin to be absent. However, since GHRP and fast-acting GHRH (Growth Hormone Releasing Hormone) products (i.e. Modified GRF 1-29) still need time to stimulate the body to release GH from the pituitary gland, the insulin spike must come after the injection and not before, otherwise the GH release will be blunted.
Amongst its metabolic effects, hGH can induce inhibition of lipoprotein lipase activity in adipose tissue, stimulating lipolysis in adipocytes, which results in the reduction of fat cell mass [4-7]. Moreover, a correlation has been found between adiposity and the reduced circulating levels of hGH [8]. When applied systemically, hGH reduces body fat mass and influences fat distribution [9]. Therefore, treatment with hGH should theoretically have a positive impact on obesity. However, long term treatment with hGH is associated with various health risks, including glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13].
The effect of a single daily ip dose of saline, AOD9604, or hGH on body weight changes in lean male C57BL/6J (A) or obese (ob/ob) mice (B) for 14 d. Caloric intake was recorded every second day and presented as an average for each day in lean (C) and obese (D) mice. Results are expressed as the mean ± SE of six animals in each group. *, P< 0.01; #, P < 0.05, compared with saline.
Both paracetamol and caffeine are regarded as being well tolerated when used at therapeutic doses and there is a low risk of serious expected or serious unexpected adverse events with these products when taken either alone or in combination. Clinical data demonstrate that paracetamol combined with caffeine significantly out performs paracetamol alone. Paracetamol/caffeine formulations are well established globally. Such formulations are marketed in over 90 countries and have been available unscheduled ranging from 14 years to 25 years. Cumulative post-marketing experience to date with the sponsor’s paracetamol/caffeine combination products is estimated to be in excess of 488 million patients and has revealed no adverse safety signals or reasons for concern with the use of this product in an open sale environment.
Background: The human growth hormone (hGH) has fat loss properties making it a potential candidate to treat obesity. AOD 9604 is a peptide fragment of the C-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD 9604 obtained in clinical trials are summarized.
The company which developed it, Metabolic Pharmaceuticals, did have a small early study done which showed a small amount of fat loss at 1 mg per day but not really any other dosing. Measured effect was less at higher doses. In total the company did at least six studies. According to the lead researcher of five of the studies, Dr Gary Wittert, results were uniformly negative.
MGF stands for mechano growth factor—a peptide derived from insulin-like growth factor-1 (IGF-1), which plays a large role in childhood development and continues to have anabolic effects throughout adulthood. MGF has the ability to encourage repair and growth of wasted tissue through the activation of muscle stem cells, thereby increasing the synthesis of proteins necessary for tissue growth. This peptide is ideal of anyone suffering from muscle loss, either due to old age or a particular condition (i.e., HIV, cancer, etc.)
When the AFL Peptides scandal hit, Calzada was forced to clarify the facts about AOD9604, and put out a cleverly worded press statement aimed at potential investors, concentrating on the fact that AOD9604 had been proven safe in large scale clinical trials (neglecting to mention a lack of effectiveness) and spoke of the success of AOD9604 on stimulating bone growth, and on cartilage and muscle cell repair in in-vitro trials (2,4). The black market uses for this peptide in muscle repair and treatment of obesity were also mentioned in the release, and it is clear through media reports on this scandal that Calzada gained traction from the profile boost (8).
We found that BNP and Nt‐proBNP concentrations were also substantially higher after weight loss surgery, both before and after saline infusion. We did not observe an acute rise in BNP or Nt‐proBNP in the first 3 hours after the saline infusion. The longer half‐lives of BNP and Nt‐proBNP may be one explanation, as these peptides may take longer to peak.16 However, we have noted a similar lack of increase after up to 8 hours of observation.17 Thus, we expect that the changes in BNP associated with surgery are likely to be substantially larger than any change induced by saline, even over longer periods of observation.
Resting plasma concentrations of mature BNP and Nt‐proBNP were 14±3 pg/mL and 42±9 pg/mL before gastric bypass surgery and increased to 32±5 pg/mL and 107±20 pg/mL (increased by 50% and 31%), respectively (P=0.0009 and 0.0001) after the surgery. Circulating BNP and Nt‐proBNP concentrations during saline infusion were also higher after surgery compared with before surgery (Figures 2A and 2B; P<0.0001). The saline infusion itself was not associated with an increase in BNP or Nt‐proBNP levels at either visit (P=0.65 and 0.60, respectively).

Between 2001 and 2006 six human clinical trials with the hexadecapeptide AOD9604 have been performed, 893 healthy, in all but one study, clinically obese adults participated in these studies and are the basis of this safety evaluation. The details of the individual studies are listed in supplementary data. The first 3 studies were dose-escalating studies investigating the acute effects of various dosages and two application routes (i.v. and oral) in healthy or obese male subjects. These single dose studies were followed by a 7-day multiple dose study (METAOD004) as well as two long-term clinical trials (METAOD005 and METAOD006) where the safety and tolerability of chronic oral treatment with AOD9604 was investigated.
The mean time (± SD) taken for recovery of normal ambulation was 25±2 days in Group 1, 15±3 days in Group 2, 16±2 days in Group 3, and 11±4 days in Group 4. The lameness period in Group 4 was significantly shorter than those in Groups 1, 2, and 3 (p<0.05). The lameness period in Group 1 was significantly longer than those in Groups 2 and 3 (p<0.05). However, there were no differences in the mean lameness period between Groups 2 and 3 (Figure 6).
Obesity affects as many as one in five adults in developed countries. Metabolic estimates that the potential worldwide market for effective obesity drugs is as much as $20 billion, far more than the current market of $1.5 billion. This is partly due to the potential need for chronically obese people to take obesity drugs such as AOD9604 and also because patients are put off using currently available drugs because of their marginal efficacy or side-effects.
Another benefit of collagen supplementation to your workout routine? Collagen contains high amounts of the amino acid arginine, which changes into nitric oxide to help our blood vessels relax and promote healthy circulation. Additionally, arginine has been found to help promote total strength and recovery in adult males (4). Adding collagen into your daily diet can help keep your bones strong, helping you to stay active and healthy.
Metabolic has just completed Phase IIA studies in a group of 22 clinically obese, but otherwise healthy, male patients ranging in age from 22?50. The results showed that the drug was well tolerated and increased fat metabolism within two hours of administration by 25 per cent in the older group of patients. Although not the focus of the study, weight loss was also demonstrated, particularly in the older group.
The Ketogenic Diet is designed to force your body into ketosis, which is a normal metabolic state. Typically, the body burns carbohydrates from food to function, but when you adopt a diet of low calories (and low carbohydrates) your body switches into ketosis. When your body is in a state of ketosis the body is burning fat for energy, meaning you are tapping into the body’s fat storage that is often the hardest to shift.
Melanotan II is an analogue of alpha melanocyte stimulating hormone, the hormone responsible for pigmentation in skin and hair. This peptide has been shown not only to increase skin pigmentation, resulting in a substantially tanner skin tone, but also to stimulate fat loss and increase libido. Its aphrodisiac effects were so substantial that it was the basis for the development of another peptide designed exclusively to address erectile and sexual dysfunction—Bremelanotide PT 141.

All peptide injections are compounded under strict sterile conditions according to USP 797 Standards. We use peptides obtained from a GMP certified manufacturer which are all over 99% pure and endotoxin tested and proven to be safe. We also perform sterility tests on all peptide preparations supplied which ensures the quality and safety of our products.
×